Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on precision genetic medicine for rare diseases, with a stated leadership position in Duchenne muscular dystrophy and an expanding portfolio across muscle, central nervous system and cardiac conditions. The SRPT news feed on Stock Titan aggregates company-issued updates and market-moving announcements that reflect Sarepta’s scientific, regulatory and financial developments.
Investors and followers of SRPT can use this page to review earnings and revenue updates, such as preliminary net product revenue reports that break out contributions from ELEVIDYS and the company’s PMO franchise, as well as quarterly financial results and commentary on cash position and capital structure. News items also cover clinical and regulatory milestones, including updates to the ELEVIDYS prescribing information, FDA safety labeling decisions, and the design and progress of studies like ENDEAVOR and ESSENCE.
The feed highlights pipeline progress in Sarepta’s next-generation siRNA platform, including clinical trial applications and early-stage data for programs such as SRP-1003 for myotonic dystrophy type 1 and SRP-1005 for Huntington’s disease. It also captures disclosures about strategic restructuring, clinical holds in limb girdle muscular dystrophy gene therapy programs, and collaborations with partners like Arrowhead Pharmaceuticals.
Corporate and capital markets news—such as convertible note exchanges, private placements of common stock, inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor conference presentations—are also included. By reviewing this consolidated SRPT news stream, users can quickly see how Sarepta communicates its progress in genetic medicine, regulatory interactions, financing activities and strategic priorities over time.
Sarepta Therapeutics (NASDAQ:SRPT) announced on May 31, 2024, the issuance of equity awards as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The awards were given to nine newly hired employees, granting a total of 8,975 restricted stock units (RSUs). The RSUs will vest in four equal installments annually over four years, subject to continuous employment. The awards were part of Sarepta's 2024 Employment Commencement Incentive Plan and approved by the Compensation Committee of the Board of Directors. No stock purchase options were granted.
Sarepta Therapeutics, Inc. announced that Dr. Jerry R. Mendell, a gene therapy pioneer, was named to the inaugural TIME100 Health list for his contributions in neuromuscular disease treatment and gene therapy advancements, notably Duchenne muscular dystrophy. Dr. Mendell's lifelong dedication to genetic medicine has significantly impacted global health.
Sarepta Therapeutics reported strong financial results for the first quarter of 2024, with net product revenues totaling $359.5 million, a 55% increase from the prior year. ELEVIDYS gene therapy generated $133.9 million in revenue. The company achieved GAAP earnings of $36.1 million and non-GAAP earnings of $78.2 million. Real-world evidence showed that eteplirsen treatment resulted in significant survival benefits for Duchenne muscular dystrophy patients. The FDA is reviewing an efficacy supplement to expand ELEVIDYS's indication.
Sarepta Therapeutics, Inc. granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 24 new employees in April 2024, comprising options to purchase 0 shares of common stock and 17,090 restricted stock units. The options have an exercise price of $126.66 per share, with vesting schedules spread over four years.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.